Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3.
To improve patient care and facilitate clinical research, the International League Against Epilepsy (ILAE) appointed a Task Force to formulate a consensus definition of drug resistant epilepsy. The overall framework of the definition has two "hierarchical" levels: Level 1 provides a general scheme to categorize response to each therapeutic intervention, including a minimum dataset of knowledge about the intervention that would be needed; Level 2 provides a core definition of drug resistant epilepsy using a set of essential criteria based on the categorization of response (from Level 1) to trials of antiepileptic drugs. It is proposed as a testable hypothesis that drug resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. This definition can be further refined when new evidence emerges. The rationale behind the definition and the principles governing its proper use are discussed, and examples to illustrate its application in clinical practice are provided.
为了改善患者护理和促进临床研究,国际抗癫痫联盟 (ILAE) 任命了一个工作组,制定耐药性癫痫的共识定义。该定义的总体框架有两个“分层”级别:第 1 级提供了一种分类治疗干预反应的一般方案,包括对干预措施的最低数据集的了解;第 2 级使用基于对(第 1 级)抗癫痫药物试验反应分类的一组基本标准,提供耐药性癫痫的核心定义。该定义提出了一个可检验的假设,即耐药性癫痫定义为未能充分进行两次耐受、适当选择和使用抗癫痫药物方案(无论是单药治疗还是联合治疗)以实现持续无癫痫发作的治疗。当出现新证据时,可以进一步细化该定义。讨论了定义背后的原理和正确使用该定义的原则,并提供了说明其在临床实践中应用的示例。